Between 2013 and 2023, the per capita market value of hormones in dosage, excluding contraceptives and antibiotics, in the UK has shown a consistent decline. Starting at $116.45 in 2013, it dropped to $43.33 by 2023. The most recent metrics indicate a year-on-year decrease of 7.23% in 2022 and 7.24% in 2023. Over the last five years, the Compound Annual Growth Rate (CAGR) was approximately -6.59%, reflecting a steady declining trend.

Future trends to watch for include:

Potential stabilizing factors such as advances in hormone therapies or regulatory changes.
The impact of new healthcare policies on hormone medication pricing.
Technological innovations in pharmaceuticals could alter demand or pricing structures.